34
347740.KQ P&K Skin Research Center Co. Ltd
- Market cap
- KRW 52.3B
- P/E
- 14.0x
- P/B
- 0.63x
- ROE
- 7.3%
- Dividend yield
- 1.87%
- Fundamental score
- 1.8/5
Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.
Is 347740.KQ undervalued?
Graham number347740.KQ trades 37.1% below its Graham number.
Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?
P&K Skin Research Center Co. Ltd fundamental analysis
9 of 22 checks passedROE 0/2
Low return on equity (7.3%), below 10%.
ROA 1/1
Return on assets (6.8%) is above the industry median (2.9%).
Profit Consistency 2/2
Profitable for 8 consecutive years.
Earnings Growth 5Y 0/1
Earnings per share did not grow over the past 5 years.
Earnings Acceleration 0/1
Last year's EPS growth (-19.4%) is not above the 5-year average (-6.5% a year).
Earnings Growth vs Industry 0/1
Last year's EPS growth (-19.4%) is below the industry median (-5.9%).
Revenue Growth 1/2
Revenue grew 8.3% a year over the past 3 years.
Short-term Liquidity 1/1
Current assets cover short-term liabilities.
Long-term Liabilities 1/1
Current assets cover long-term liabilities.
Debt to Equity 0/2
Debt to equity cannot be calculated: debt is not reported or equity is negative.
Debt Trend 0/1
Debt to equity has risen over the past 5 years.
Debt Coverage 0/1
Debt is not reported.
Interest Coverage 1/1
No interest expense reported.
PE vs Market 0/1
PE (14.0x) is above the market median (11.3x).
PE vs Industry 0/1
PE (14.0x) is above the industry median (12.8x).
PBV 0/1
Price to book (0.6x) is above the industry median (0.6x).
Graham Number 1/1
The price is below the Graham number (PE x PB = 8.9, limit 22.5).
PEG 0/1
PEG needs positive PE and positive 5-year earnings growth.
Dividend Yield 1/2
Dividend yield (1.9%) is above the bottom 25% of dividend payers in the market.
Dividend Stability 0/2
Dividends were not paid steadily for the past 5 years.
Dividend Growth 0/1
Dividends paid did not grow over the past 5 years.
Payout Ratio 1/1
Payout ratio is 20.9%, covered by earnings.
Each check is worth 1 or 2 points by how much it says about the quality of the company. The score is the share of points earned, out of 5. Ask AI to explain this score
P&K Skin Research Center Co. Ltd stock price
Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.
About P&K Skin Research Center Co. Ltd
P&K Skin Research Center Co., Ltd. engages in the evaluation and research of dermatological products in South Korea. It provides scientific information and technical support services for new cosmetic raw material development, functional cosmetics, and human application testing of quasi-drugs. The company performs human application, safety, efficacy, cosmeceuticals, health food, sensory, and in vitro tests. It also manufactures and sells raw pharmaceutical and cosmetic materi…
Full company profileP&K Skin Research Center Co. Ltd financial statements
2026 annualized: Fiscal year 2026 is not finished. Income statement and cash flow are annualized from 2 quarters up to Jun 30, 2026, the balance sheet is the latest quarter. Figures change when the annual report is published.
P&K Skin Research Center Co. Ltd annual financial statements (KRW; K = thousand, M = million, B = billion, T = trillion)
| Item | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 Anlz |
|---|---|---|---|---|---|---|---|---|---|
| Income Statement | |||||||||
| Revenue | 10.0B | 12.5B | 14.7B | 17.5B | 18.0B | 14.8B | 17.8B | 22.8B | 25.7B |
| Gross Profit | 7.40B | 9.15B | 10.3B | 11.3B | 11.1B | 7.20B | 8.48B | 10.7B | 12.6B |
| Operating Income | 4.57B | 5.68B | 7.22B | 6.46B | 5.64B | 1.38B | 2.58B | 3.94B | 4.94B |
| EBITDA | - | - | - | - | 9.68B | 7.12B | 8.67B | 7.86B | 7.72B |
| Net Income | 3.88B | 5.38B | 6.72B | 7.29B | 7.13B | 4.81B | 5.82B | 4.69B | 6.03B |
| EPS | 136 | 224 | 227 | 246 | 238 | 160 | 201 | 162 | 209 |
| Balance Sheet | |||||||||
| Total Assets | 17.6B | 28.0B | 59.9B | 67.1B | 74.5B | 77.4B | 82.0B | 86.5B | 88.4B |
| Total Liabilities | 1.68B | 3.47B | 4.27B | 4.03B | 3.73B | 3.17B | 5.10B | 6.04B | 6.19B |
| Shareholders' Equity | 16.0B | 24.5B | 55.6B | 63.1B | 70.8B | 74.2B | 76.9B | 80.6B | 82.4B |
| Cash & Short-term Investments | 11.4B | 22.8B | 49.7B | 42.2B | 57.5B | 44.7B | 40.7B | 3.97B | 2.75B |
| Total Debt | - | 750M | 622M | - | - | - | - | - | - |
| Cash Flow | |||||||||
| Operating Cash Flow | 4.26B | 6.49B | 8.67B | 7.70B | 7.51B | 5.55B | 9.03B | 6.68B | 5.71B |
| Capital Expenditure | 656M | 541M | 1.05B | 2.81B | 1.36B | 1.56B | 622M | 1.50B | 1.54B |
| Free Cash Flow | - | 6.38B | 7.61B | 4.89B | 6.15B | 3.99B | 8.41B | 5.18B | 4.17B |
| Ratios | |||||||||
| ROE | 24.3% | 21.9% | 12.1% | 11.6% | 10.1% | 6.5% | 7.6% | 5.8% | 7.3% |
| ROA | 22.0% | 19.2% | 11.2% | 10.9% | 9.6% | 6.2% | 7.1% | 5.4% | 6.8% |
| Net Profit Margin | 38.8% | 43.0% | 45.8% | 41.7% | 39.7% | 32.4% | 32.6% | 20.6% | 23.5% |
| Debt to Equity | - | 0.03x | 0.01x | - | - | - | - | - | - |
What these items mean
- Revenue
- Total sales of goods and services in the period.
- Gross Profit
- Revenue minus the direct cost of producing what was sold.
- Operating Income
- Profit from the core business after operating expenses.
- EBITDA
- Earnings before interest, taxes, depreciation and amortization.
- Net Income
- Profit left for shareholders after all expenses, interest and taxes.
- EPS
- Net income divided by shares outstanding.
- Total Assets
- Everything the company owns.
- Total Liabilities
- Everything the company owes.
- Shareholders' Equity
- Assets minus liabilities: the book value that belongs to shareholders.
- Cash & Short-term Investments
- Cash and investments that can be turned into cash quickly.
- Total Debt
- Short and long-term borrowings.
- Operating Cash Flow
- Cash generated by the core business.
- Capital Expenditure
- Cash spent on property, plant and equipment.
- Free Cash Flow
- Operating cash flow minus capital expenditure: cash left for dividends, buybacks or debt repayment.
- ROE
- Return on equity: net income divided by shareholders' equity.
- ROA
- Return on assets: net income divided by total assets.
- Net Profit Margin
- Net income as a share of revenue.
- Debt to Equity
- Total debt divided by shareholders' equity.
P&K Skin Research Center Co. Ltd dividends
- Dividend yield
- 1.87%
- Forward dividend
- 50.00 KRW
- Payout ratio
- 20.9%
- Ex-dividend date
- Dec 29, 2025
| Fiscal year | Dividends paid | Per share | Payout ratio |
|---|---|---|---|
| 2025 | KRW 977M | 34 | 20.9% |
| 2024 | KRW 715M | 25 | 12.3% |
| 2023 | KRW 872M | 29 | 18.1% |
| 2022 | KRW 893M | 30 | 12.5% |
| 2021 | - | - | - |
| 2020 | - | - | - |
| 2019 | - | - | - |
| 2018 | - | - | - |
From the cash flow statement: dividends paid in the fiscal year, divided by that year's shares outstanding. Payout ratio = dividends paid / net income.
Last stock split: 4:1 on Jul 26, 2022.
Who owns P&K Skin Research Center Co. Ltd
- Insiders 59.41%
- Institutions 0.16%
- Public & others 40.43%
- Shares outstanding 28.9M
- Free float 11.1M
P&K Skin Research Center Co. Ltd company profile
- Company name
- P&K Skin Research Center Co. Ltd
- Ticker
- 347740.KQ
- ISIN
- KR7347740003
- Exchange
- KOSDAQ
- Sector
- Healthcare
- Industry
- Commercial Services & Supplies
- Employees
- 98
- Fiscal year end
- December
- Address
- Korea Educational Facility Safety Institute, Seoul, South Korea, 07236
- Phone
- 82 2 6925 1502
- Website
- pnkskin.com
About P&K Skin Research Center Co. Ltd
P&K Skin Research Center Co., Ltd. engages in the evaluation and research of dermatological products in South Korea. It provides scientific information and technical support services for new cosmetic raw material development, functional cosmetics, and human application testing of quasi-drugs. The company performs human application, safety, efficacy, cosmeceuticals, health food, sensory, and in vitro tests. It also manufactures and sells raw pharmaceutical and cosmetic materials, and raw materials for health foods. The company was founded in 2010 and is headquartered in Seoul, South Korea. P&K Skin Research Center Co., Ltd. is a subsidiary of Daebongls.Co.,Ltd.
P&K Skin Research Center Co. Ltd management
1- Hae-gwang LeeChief Executive Officer